Hepatocyte growth factor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-28. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
== History == The organization's roots traces back to the 19th century with the foundation of the British Indian Army, a Public Works Department was established in the mid-1850s to oversee engineering and construction works while under the control of the Military Board and manned by personnel from the Engineering Corps. It had three branches, Military Works Branch and Civil Works Branch. In 1899, the organization was renamed as Military Works Services and placed under direct command of the Director General Military Works (DGMW). It was finally termed to its current name in 1923. By this time, the organization of the Engineer-in-Chief for British India was based on the workload of the MES. It was divided into four regional commands:-
==== Blood tests ==== Blood tests play an important role in the diagnosis and treatment of many cardiovascular conditions. Troponin is a sensitive biomarker for a heart with insufficient blood supply. It is released 4–6 hours after injury and usually peaks at about 12–24 hours. Two tests of troponin are often taken—one at the time of initial presentation and another within 3–6 hours, with either a high level or a significant rise being diagnostic. A test for brain natriuretic peptide (BNP) can be used to evaluate for the presence of heart failure, and rises when there is increased demand on the left ventricle. These tests are considered biomarkers because they are highly specific for cardiac disease. Testing for the MB form of creatine kinase provides information about the heart's blood supply, but is used less frequently because it is less specific and sensitive. Other blood tests are often taken to help understand a person's general health and risk factors that may contribute to heart disease. These often include a full blood count investigating for anaemia, and basic metabolic panel that may reveal any disturbances in electrolytes. A coagulation screen is often required to ensure that the right level of anticoagulation is given. Fasting lipids and fasting blood glucose (or an HbA1c level) are often ordered to evaluate a person's cholesterol and diabetes status, respectively.
==== Cardiotoxins / Cytotoxins ==== Cardiotoxins are components that are specifically toxic to the heart. They bind to particular sites on the surface of muscle cells and cause depolarisation → the toxin prevents muscle contraction. These toxins may cause the heart to beat irregularly or stop beating, causing death. An example is the three-fingered cardiotoxin III from Chinese cobra, an example of the short three-fingered family (InterPro: IPR003572). Snake example: mambas, and some Naja species
== External links == BURDEN of Resistance and Disease in European Nations – An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals Cochrane Wounds list of antimicrobials (PDF) National Pesticide Information Center Overview of the use of Antimicrobials in plastic applications The Antimicrobial Index – A continuously updated list of antimicrobial agents found in scientific literature (includes plant extracts and peptides)
=== Antidotes === Andexxa (Andexanet alfa) from Portola Pharmaceuticals is a recombinant protein that is given intravenously. It works as an antidote to all direct and indirect FXa inhibitors. Andexxa acts as a decoy receptor for Xa inhibitors.
Sources: en.wikipedia.org
The positive side of freedom of association is that the law protects everyone against adverse action for joining a union, and also taking part in collective action including strikes that count as "protected industrial action". If an employee alleges that the employer has taken adverse action for a prohibited reason, "it is presumed that the action was, or is being, taken for that reason or with that intent, unless the [employer] proves otherwise." The claimant may apply to the Fair Work Commission which holds a conference, compulsory in cases of dismissal, and the FWC may arbitrate with the parties' consent. Despite the intent of Parliament, in Board of Bendigo Regional Institute of Technical and Further Education v Barclay the High Court held that the reverse burden of proof made it legitimate to focus on the subjective reasons of the decision-maker, so that direct "testimony from the decision-maker which is accepted as reliable is capable of discharging the burden", and that this achieved a "balance". The High Court repeated this stance in CFMEU v BHP Coal Pty Ltd, where a striking worker held a sign saying "No principles SCABS No Guts", and was dismissed for violating BHP's "workplace conduct policy". The High Court sided with the employer's assertion that dismissal was for uncivil language, not union activity, and said that a claimant would only be protected from an employer's deliberate and conscious victimisation, not employers who make out they (supposedly) inadvertently took adverse action.
The structure of the EcM network depends on the availability of nutrients. When nutrient availability is low, the investment in the underground network is high relative to above-ground growth. Phosphorus is another typically limiting nutrient in many terrestrial ecosystems. Evidence suggests that phosphorus is transferred largely as orthophosphate. Some mat-forming ectomycorrhizas contain ribonucleases capable of rapidly degrading DNA to obtain phosphorus from nuclei.
=== People's Party === People's Party leader Natthaphong Ruengpanyawut accepted the preliminary results that indicated the party was unlikely to finish first. After thanking voters, Natthaphong remarked how the constitutional referendum appeared to be approved by the public. He agreed that the party would respect parliamentary process, and to lead the opposition if Bhumjaithai managed to form a government. Natthaphong reiterated that it would not join a government led by a Bhumjaithai prime minister and that it would not form a rival coalition against a potential Bhumjaithai government.
In 2004, a group of ACS members criticized the compensation of former executive director and chief executive officer John Crum, whose total salary, expenses, and bonuses for 2002 was reported to be $767,834. The ACS defended the figure, saying that it was in line with that of comparable organizations, including for-profit publishers. As of 2016, two employees were reported to have a total compensation exceeding $900,000, while 694 had a compensation exceeding $100,000. Reagent Chemicals (Reagent ACS), standards of chemical purity ACS style, the ACS's citation standard Association for Learned and Professional Society Publishers Chemical Abstracts Service List of learned societies List of international professional associations National Chemistry Week National Historic Chemical Landmarks
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.